Current trends in treatment of transient ischemic attacks
Related Experiment Videos
Insights
Transient ischemic attacks (TIAs) require individualized treatment focusing on preventing stroke and vascular death. Key strategies include managing risk factors and using antiplatelet drugs like aspirin or ticlopidine.
Area of Science:
- Neurology
- Vascular Medicine
- Pharmacology
Background:
- Transient ischemic attacks (TIAs) are critical warning signs for potential cerebral infarction and vascular death.
- Effective management of TIAs involves a multi-faceted approach addressing underlying risk factors and employing appropriate pharmacotherapy.
Purpose of the Study:
- To review current treatment trends for transient ischemic attacks (TIAs).
- To outline strategies for preventing cerebral infarction and vascular death in TIA patients.
- To discuss the role of risk factor management and antiplatelet/anticoagulant therapies.
Main Methods:
- Review of current literature and treatment guidelines for TIAs.
- Analysis of risk factor management strategies including hypertension, dyslipidemia, diabetes, and lifestyle modifications.
- Evaluation of antiplatelet (aspirin, ticlopidine) and anticoagulant therapies, including combination strategies.
- Consideration of surgical interventions like carotid endarterectomy in the context of concurrent coronary artery disease.
Main Results:
- Individualized treatment is crucial for TIA patients to prevent stroke and vascular death.
- Control of risk factors (hypertension, dyslipidemia, diabetes, atrial fibrillation, overweight) and lifestyle changes (diet, exercise, smoking cessation) are essential.
- Aspirin (325 mg/day) is effective and safer than higher doses; ticlopidine is considered a highly effective antiplatelet agent.
- Combination therapy (warfarin with ticlopidine) or sequential therapy (anticoagulants followed by antiplatelets) may be used for recurrent TIAs.
- Treatment of coronary artery disease prior to carotid endarterectomy may improve survival.
Conclusions:
- Optimal TIA management integrates aggressive risk factor control with judicious use of antiplatelet or anticoagulant medications.
- Ticlopidine represents a significant advancement in antiplatelet therapy for TIAs.
- The role and effectiveness of carotid endarterectomy are still under active investigation in ongoing clinical trials.
Abstract:
Current trends in treatment of transient ischemic attacks (TIAs) are reviewed. Patients with TIAs should be treated individually, the main goals of therapy being to avoid cerebral infarction and vascular death. Management of risk factors includes control of high blood pressure, dyslipoproteinemias, diabetes mellitus, atrial fibrillation, cardiac arrhythmias, and overweight. A healthy diet, exercising and non-smoking are additional useful measures. The most commonly used antiplatelet drug is aspirin. Doses of 325 mg per day are as effective as doses of 1,300 mg per day but have fewer side effects. Ticlopidine seems the best antiplatelet drug currently available; it is given in doses of 500 mg per day for a month and then 250 mg per day for the rest of the patient's life. Anticoagulants have not shown their advantages over drugs that prevent platelet aggregation. However, when a patient under treatment with warfarin with an adequate dose range suffers recurrent TIAs, warfarin can be used in association with ticlopidine. On the other hand, if patients under treatment with ticlopidine have further TIAs, they should be switched to anticoagulants for 6 months and then back to antiplatelet drugs. With regard to surgery, an effective means of prolonging survival seems to be the treatment of coronary artery disease before carotid endarterectomy is considered. The effectiveness of carotid endarterectomy is being evaluated in ongoing multicentric, randomized, controlled clinical trials.